[关键词]
[摘要]
糖尿病性黄斑水肿(diabetic macular edema， DME)是糖尿病患者眼部常见的并发症之一，也是导致糖尿病患者视力损伤的主要原因。血管内皮生长因子(vascular endothelial growth factor，VEGF)是目前DME治疗的重要靶点。目前对DME的主要治疗药物包括抗血管内皮生长因子和糖皮质激素(corticosteroid)； 尚在发展中的新兴治疗药物有抗VEGF DARPin设计的锚蛋白重复序列(designed ankyrin repeat proteins，DARPins)、血管黏附蛋白(vascular adhesion protein)和整合素拮抗剂(integrin antagonist)等。本文就糖尿病性黄斑水肿的药物治疗及进展作一综述。
[Key word]
[Abstract]
Diabetic macular edema(DME)is one of the common eye complications in diabetic patients, and is also the main cause of visual impairment in diabetic patients. Vascular endothelial growth factor(VEGF)is currently an important target for DME therapy, the latest DME guidelines point out that anti-VEGF can be used as a first-line treatment for all types of DME. Anti-VEGF and glucocorticoid are widely used medications in DME treatment at present. Besides, numbers of new therapies which include anti-VEGF DARPin(designed ankyrin repeat proteins, DARPins), vascular adhesion protein, integrin antagonists and others, are in development. This article reviews the medication and emerging treatment of diabetic macular edema.
[中图分类号]
[基金项目]
深圳市卫生计生系统科研项目(No.SZLY2017027)
